August 2012
-
3M Drug Delivery Systems and Impel NeuroPharma have announced that the two companies will collaborate on development and commercialization of Impel’s Precision Olfactory Delivery (POD) platform for intranasal delivery of drugs to the central nervous… Read more . . .
-
Serendex Pharmaceuticals has announced that data from a Phase 1 randomized, double blind, placebo controlled single ascending dose/multiple ascending dose trial showed that Molgradex inhaled GM-CSF (molgramostim) was well tolerated at all dose levels. No… Read more . . .
-
A Phase 2 study of Invion’s INV102 inhaled nadolol showed that smokers using the therapy were much more likely to stop smoking or significantly reduce the number of cigarettes they smoked than those using a… Read more . . .
-
Celdara Medical and Pulmatrix have been awarded a 3-year $1.7 million Fast Track Small Business Innovation Research grant from the National Heart Lung and Blood Institute (NHLBI) for development of an inhaled therapy for the… Read more . . .
-
Alexza Pharmaceuticals has promoted Catherine McAuliffe to VP, Operations and Stacy Palermini to VP, Finance, the company said. McAuliffe most recently served as Executive Director, Operations; the position of VP, Operations is newly created. Palermini… Read more . . .
-
GlaxoSmithKline has exercised an option for an exclusive license to develop inhaled therapies using Liquidia Techonologies’ PRINT particle engineering technology, Liquidia said. The option was included in a collaboration deal the two companies signed in… Read more . . .
-
Verona Pharma has announce that data from the third part of single ascending dose (SAD)/multiple ascending dose (MAD) trial of nebulized RPL554 in COPD patients show that the formulation was well tolerated at all doses… Read more . . .
-
Hovione, which offers a wide range of inhalation drug development and manufacturing services, has announced that it will add 30,600 sq ft and a new commercial spray dryer to its East Windsor, NJ facility. The… Read more . . .
-
Boehringer Ingelheim has announced new data from the ENERGITO and OTEMTO studies of the Stiolto tiotropium/olodaterol Respimat inhaler for the treatment of COPD. The FDA approved Stiolto Respimat in May 2015; in Europe, where the… Read more . . .
-
Teva Pharmaceutical has acquired privately held Gecko Health Innovations and its CareTRx asthma and COPD management system. CareTRx works with a monitoring device called GeckoCap that attaches to an MDI plus a mobile phone app.… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland